Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

272

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

TA-7284 Low

The patients will receive TA-7284-Low orally for 24 weeks.

DRUG

TA-7284 High

The patients will receive TA-7284-High orally for 24 weeks.

DRUG

Placebo

The patients will receive Placebo orally for 24 weeks.

Trial Locations (5)

Unknown

Reserch site, Chūbu

Reserch site, Kanto

Reserch site, Kinki

Reserch site, Shikoku

Reserch site, Tōhoku

All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY